ENVALITH
株式会社ジェイホールディングス logo

J-Holdings Corp.

2721・Standard Market・Wholesale Trade

Official website
株式会社ジェイホールディングス logo
J-Holdings Corp.2721

Business

J Holdings Co., Ltd. is a holding company founded in 1993 and listed in 2004 on the TSE Standard Market. It maintains futsal facility operation (Sports Business) and industrial waste treatment (Environmental Solutions Business) as its existing revenue base, while concentrating management resources on grid-connected storage battery development and operation (Energy-related Business) and exosome purification and sales (Regenerative Medicine-related Business) as new growth businesses. The company also operates a Real Estate Business (fundraising advisory services for owners of business-use assets), though this has not yet generated recorded revenue. The Web Business was dissolved and liquidated in August 2025 and no longer exists. The group consists of 6 consolidated subsidiaries, with major customers including futsal facility users, industrial waste-generating businesses, and affiliated clinics, among others.

Business Model

The Sports Business (net sales ¥114 million, operating margin 27.5%) and the Environmental Solutions Business (net sales ¥70 million, operating profit ¥9 million) are currently the sole sources of profit. Meanwhile, in the Energy-related Business, the company plans to acquire and operate grid-connected storage battery facilities through a capital and business alliance with Taiwan's Recharge Power, and in the Regenerative Medicine-related Business, the cell culture processing facility "RegenTech Lab" (total cost approximately ¥200 million) began operations in December 2025. The structure relies on external fundraising through the exercise of stock acquisition rights and silent partnership (tokumei kumiai) investments to cover upfront costs for these new businesses.

Company Strengths

Operated two futsal facilities (Kanagawa and Hyogo prefectures), achieving net sales of ¥114 million, operating profit of ¥31 million, and an operating profit margin of 27.5%. At the Tsukashin location, membership increased due to enhanced junior school programs, while at the Higashiyamada location, cost reduction measures resulted in lower revenue but higher profit. Operating profit grew 10.9% year-on-year.

HB Corporation, which operates a stable-type final disposal site in Kurashiki City, Okayama Prefecture, saw its goodwill amortization expense burden disappear following a full impairment of goodwill in FY2024 (ending December 2024) (compared to goodwill amortization expense of ¥53,432 thousand in the prior period). In FY2025 (ending December 2025), the company posted net sales of ¥70 million and operating profit of ¥9 million, a significant turnaround from an operating loss of ¥48,844 thousand in the prior period.

In FY2025 (ending December 2025), the exercise of stock acquisition rights increased common stock and capital reserves by ¥201,006 thousand each, achieving a total capital increase of ¥402,012 thousand and resolving the capital deficiency. Furthermore, in February 2026, the company plans to issue the 10th and 11th series of stock acquisition rights (202,700 units in total), with plans to raise up to approximately ¥4,070 million in additional funding.

ENVALITH's Perspective

In Q1 FY2026 (ending December 2026), the company recorded an operating loss of ¥65 million, ordinary loss of ¥65 million, and quarterly net loss of ¥65 million. While the loss narrowed from the same period a year earlier (operating loss of ¥87 million), the structural deficit condition continues. In addition to the operating loss, ordinary loss, net loss, and negative operating cash flow recorded in the previous fiscal year, the recording of similar losses in the current quarter has led to a formal note regarding material uncertainty about the going concern assumption. Accumulated deficit in retained earnings has reached ¥1,033 million, indicating high financial fragility.

Net sales for Q1 FY2026 (ending December 2026) reached ¥79 million, a 148.4% increase year-on-year. This was mainly driven by the rapid expansion of the environmental solutions business (¥33 million) and new sales from the regenerative medicine-related business (¥18 million). However, the full-year sales forecast is ¥453 million (up 138.9% year-on-year), meaning Q1 progress stood at only 17.4%. The energy-related business and the financial business recorded zero sales in Q1, making it essential to book large-scale projects in the second half in order to achieve the full-year forecast. In particular, whether the planned acquisition of a grid-connected battery storage facility scheduled for December 2026 proceeds as planned will be the biggest focal point.

Between January 2026 and May 15, 2026, 1,480,000 new shares were issued, increasing the number of shares outstanding from 9,728,500 to 10,288,500. Furthermore, as a subsequent event, an additional issuance of 920,000 shares has been confirmed from April 2026 onward, indicating that dilution is ongoing. The full-year forecast for net loss per share is -¥15.76, which reportedly already reflects the impact of the new share issuances. While the need for fundraising is understandable, continued dilution is disadvantageous to existing shareholders, and there is an urgent need to shift toward self-sustaining cash generation through the monetization of new businesses.

Growth Strategy

The company aims to resolve its structural deficit through early monetization of the grid-connected battery storage and regenerative medicine businesses, combined with maintaining stable earnings from its two existing businesses.

The company entered into a capital and business alliance with Taiwan's Recharge Power, planning to acquire and self-operate domestic grid-connected battery storage facilities with a total investment of approximately ¥15.0 billion. One of the planned acquisitions is scheduled for December 2026, with early revenue contribution expected. The company also plans to maximize profitability through an AI-powered automated bidding system.

The company began purifying and selling exosomes at its cell culture processing facility, completed in December 2025, recording sales of ¥18 million in Q1 of FY2026 (ending December 2026). Going forward, after obtaining a manufacturing license for specified processed cells, the company plans to enter the contract culturing and processing business for somatic stem cells commissioned by medical institutions and others, aiming to expand its sales scale.

The continued operation of the stabilized-type final landfill disposal site in Kurashiki City, Okayama Prefecture, stabilizes the group's earnings base. In Q1 of FY2026 (ending December 2026), the business achieved a significant increase in both revenue and profit, with sales of ¥33 million and operating profit of ¥13 million. The improvement in the earnings structure following the elimination of goodwill amortization expenses has taken hold, and stable profit contribution is expected.

Subsidiary J-Lead Partners provides fundraising advisory services using direct financing methods for owners of real estate and solar power generation facilities, aiming to generate revenue. In Q1 of FY2026 (ending December 2026), the business recorded zero sales and an operating loss of ¥8 million, with monetization yet to be achieved, making new deal acquisition an urgent priority. The segment name was changed from

The company continues to raise funds through the phased exercise of its 8th, 10th, and 11th series of stock acquisition rights. It raised ¥91 million in Q1 of FY2026 (ending December 2026), and as a subsequent event, an additional exercise equivalent to ¥112 million has been confirmed since April 2026. This is an important measure to support cash flow until the new businesses achieve profitability.

Last updated: July 17, 2026